puromycin aminonucleoside has been researched along with Hyperlipemia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaneko, K; Kaneshiro, Y; Matsuo, T; Nakajima, K; Ohno, Y; Tanaka, H; Yamashita, J | 1 |
| Chen, J; Fu, W; Lei, Y; Ruan, J; Wu, G; Xiong, C; Zhang, Y | 1 |
| CENCIOTTI, L; MARIOTTI, A | 1 |
| Hattori, T; Ito, M; Nagamatsu, T; Suzuki, Y | 1 |
| Hernández, A; Mendoza-Figueroa, T; Nuño, P; Panduro, A | 1 |
| Granados-Silvestre, MA; Hernández-Pando, R; Maldonado, PD; Medina-Campos, ON; Olivares-Corichi, IM; Pedraza-Chaverrí, J | 1 |
| Edwards, KD; Schapel, GJ | 1 |
| Hirano, T; Morohoshi, T | 1 |
| Chiba, S; Obara, K; Saito, T; Sato, H; Shoji, Y; Soma, J; Yoshinaga, K | 1 |
| Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T | 1 |
| Hirano, T; Mamo, JC; Ohnami, K; Sugisaki, T | 1 |
| Eilam, O; Shafrir, E; Yedgar, S | 1 |
12 other study(ies) available for puromycin aminonucleoside and Hyperlipemia
| Article | Year |
|---|---|
Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
Topics: Animals; Anticoagulants; Antithrombins; Apoptosis; Blood Coagulation; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Hyperlipidemias; In Situ Nick-End Labeling; Injections, Intravenous; Kidney; Nephrotic Syndrome; Proteinuria; Puromycin Aminonucleoside; Rats; Thrombin; Time Factors | 2008 |
Renoprotective potential of Macrothelypteris torresiana via ameliorating oxidative stress and proinflammatory cytokines.
Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Ferns; Hyperlipidemias; Kidney; Lipid Peroxidation; Lipids; Male; Mice; Nephrotic Syndrome; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; Phytotherapy; Polyphenols; Potassium Dichromate; Protective Agents; Puromycin Aminonucleoside; Vascular Endothelial Growth Factor A | 2012 |
[The importance of the reticuloendothelial system in the pathogenesis of hyperlipidemia in experimental aminonucleoside-induced nephrosis. Preliminary note].
Topics: Hyperlipidemias; Lipids; Mononuclear Phagocyte System; Nephrosis; Nucleosides; Nucleotides; Puromycin Aminonucleoside | 1961 |
The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats.
Topics: Animals; Anticholesteremic Agents; Azathioprine; CD4-Positive T-Lymphocytes; Cholestyramine Resin; Clofibrate; Cyclosporine; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Glomerulus; Leukocytes, Mononuclear; Male; Nephrosis; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-2 | 1996 |
Viscosity regulates apolipoprotein A-1 gene expression in experimental models of secondary hyperlipidemia and in cultured hepatocytes.
Topics: Animals; Apolipoprotein A-I; Carbon Tetrachloride; Cells, Cultured; Colloids; Culture Media; Gene Expression Regulation; Hyperlipidemias; Liver; Liver Regeneration; Male; Nephrotic Syndrome; Osmotic Pressure; Puromycin Aminonucleoside; Rats; Rats, Wistar; RNA, Messenger; Viscosity | 1997 |
Garlic ameliorates hyperlipidemia in chronic aminonucleoside nephrosis.
Topics: Animals; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Disease Models, Animal; Garlic; Glutathione Peroxidase; Hydrogen Peroxide; Hyperlipidemias; Hypolipidemic Agents; Kidney; Male; Nephrotic Syndrome; Phytotherapy; Plants, Medicinal; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Wistar; Superoxide Dismutase; Triglycerides | 2000 |
Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
Topics: Animals; Body Weight; Butyrates; Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination; Female; Glycolates; Halofenate; Hyperlipidemias; Lipids; Liver; Nephrotic Syndrome; Organ Size; Oxandrolone; Puromycin Aminonucleoside; Rats; Statistics as Topic | 1975 |
Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
Topics: Animals; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Male; Nephrotic Syndrome; Probucol; Puromycin Aminonucleoside; Rats; Rats, Inbred Strains | 1992 |
Administration of Triton WR 1339 aggravates chronic aminonucleoside nephrosis.
Topics: Animals; Cholesterol; Chronic Disease; Disease Models, Animal; Drug Synergism; Hyperlipidemias; Injections, Intravenous; Lipid Metabolism; Male; Nephrosis; Polyethylene Glycols; Puromycin Aminonucleoside; Rats; Rats, Inbred Strains; Triglycerides | 1992 |
The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Hyperlipoproteinemias; Kidney; Male; Nephrotic Syndrome; Organ Size; Probucol; Proteinuria; Puromycin Aminonucleoside; Rats | 1991 |
Treatment of hyperlipidemia with probucol reduces proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Male; Nephrotic Syndrome; Phenols; Probucol; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Inbred Strains | 1990 |
Regulation of plasma lipid levels by plasma viscosity in nephrotic rats.
Topics: Animals; Blood Viscosity; Cholesterol; Hyperlipidemias; Lipids; Lipoproteins; Male; Nephrotic Syndrome; Puromycin Aminonucleoside; Rats; Rats, Inbred Strains; Triglycerides | 1985 |